Comment
doi: 10.1007/s00415-019-09485-9.
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
Affiliations
- PMID: 31372734
- PMCID: PMC6687691
- DOI: 10.1007/s00415-019-09485-9
Item in Clipboard
Comment
Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
J Neurol.
2019 Sep.
No abstract available
Comment on
-
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Clinical Trial.
-
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone.J Neurol. 2018 Sep;265(9):2052-2059. doi: 10.1007/s00415-018-8948-y. Epub 2018 Jul 2. J Neurol. 2018. PMID: 29968199 Free PMC article.
-
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9. Lancet Neurol. 2018. PMID: 30001923 Clinical Trial.
Similar articles
-
Intravenous versus subcutaneous immunoglobulin.Lancet Neurol. 2018 May;17(5):393. doi: 10.1016/S1474-4422(18)30106-6. Lancet Neurol. 2018. PMID: 29656737 No abstract available.
-
[Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].Rinsho Shinkeigaku. 2006 Mar;46(3):236-8. Rinsho Shinkeigaku. 2006. PMID: 16642939 Japanese.
-
Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.Lancet Neurol. 2012 Jun;11(6):493-502. doi: 10.1016/S1474-4422(12)70093-5. Epub 2012 May 10. Lancet Neurol. 2012. PMID: 22578914 Clinical Trial.
-
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.Expert Rev Neurother. 2009 Jun;9(6):789-95. doi: 10.1586/ern.09.30. Expert Rev Neurother. 2009. PMID: 19496683 Review.
-
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.J Peripher Nerv Syst. 2017 Dec;22(4):425-432. doi: 10.1111/jns.12242. Epub 2017 Nov 21. J Peripher Nerv Syst. 2017. PMID: 29092099 Review.
Cited by
-
Intravenous human immunoglobulin utilization patterns and cost analysis in a Malaysian tertiary referral hospital.J Pharm Policy Pract. 2022 Apr 26;15(1):31. doi: 10.1186/s40545-022-00430-2. J Pharm Policy Pract. 2022. PMID: 35473939 Free PMC article.
-
Dealing With Immunoglobulin Shortages: A Rationalization Plan From Evidence-Based and Data Collection.Front Public Health. 2022 May 19;10:893770. doi: 10.3389/fpubh.2022.893770. eCollection 2022. Front Public Health. 2022. PMID: 35664094 Free PMC article.
-
Brazilian Academy of Neurology recommendations for diagnosis, management, and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).Arq Neuropsiquiatr. 2025 Jul;83(7):1-19. doi: 10.1055/s-0045-1809884. Epub 2025 Jul 28. Arq Neuropsiquiatr. 2025. PMID: 40720971 Free PMC article.
-
Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.Front Pharmacol. 2024 Dec 16;15:1420682. doi: 10.3389/fphar.2024.1420682. eCollection 2024. Front Pharmacol. 2024. PMID: 39737065 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
